Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Open Access
- 1 May 2009
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 20 (suppl_4), iv126-iv128
- https://doi.org/10.1093/annonc/mdp151
Abstract
The incidence of malignant glioma is approximately 5/100 000. Malignant glioma may develop at all ages, the peak incidence being in the fifth and sixth decades of life.Keywords
This publication has 26 references indexed in Scilit:
- Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answersAnnals of Oncology, 2008
- Chemoradiotherapy in Malignant Glioma: Standard of Care and Future DirectionsJournal of Clinical Oncology, 2007
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006
- Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of ResponseJournal of Clinical Oncology, 2006
- Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trialActa Neurochirurgica, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971Journal of Clinical Oncology, 2003
- A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant gliomaNeuro-Oncology, 2003
- A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalJournal of Neurosurgery, 2001
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000